ArticleJournal of molecular histology2025
Neurotensin receptor1 signaling promotes progression of epithelial-mesenchymal transition in mice with chronic rhinosinusitis through Wnt3a/β-catenin pathway.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Chronic rhinosinusitis (CRS) is a multifactorial inflammatory disease characterized by high prevalence and morbidity.Epithelial-to-mesenchymal transition (EMT) is associated with the pathophysiology of chronic rhinosinusitis with nasal polyp (CRSwNP).Since Neurotensin receptor 1 (NTSR1) signaling has been shown to regulate the EMT process in other diseases.In this study, we investigated the effect of NTSR1 on the EMT process in CRS, and explored whether these regulations could serve as potential drug targets.Our results demonstrated that NTS and NTSR1 expression was significantly elevated in CRS mice who were accompanied with mucosal thickening, goblet cell hyperplasia, glandular hyperplasia, and dense infiltration of inflammatory cells.Treatment with NTSR1 inhibitor SR48692 significantly improved the nasal symptoms and pathological conditions of sinus mucosa tissues in CRS mice.In addition, SR48692 treatment significantly downregulated the mRNA expression of Th2 cytokines (IL-4 and IL-5) and IL-17. Moreover, we observed that treatment with SR48692 significantly reduced the expression of a-SMA and vimentin, while increased that of E-cadherin, suggesting inhibition of EMT.Mechanistically, we further found that SR48692 could downregulate Wnt3a and β-catenin mRNA and protein levels impairing the Wnt/β-catenin pathway.Our results indicate that NTSR1 signaling promotes progression of EMT in mice with CRS may through Wnt3a/β-catenin pathway, underlining the promise of NTSR1 as a potential target for CRS therapy.
Indexed as
Identifiers
40768090What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.